This review aims to provide a comprehensive overview of the current understanding of PI3K signaling in lung cancer, encompassing the distinct functions of PI3K subtypes, the therapeutic landscape of PI3K inhibitors, their impact on immune modulation within the TME, and their role in metabolic control. This evidence concerns the gene PIK3CA and lung carcinoma.